BS_X91K8KMG
pilocytic astrocytoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- pilocytic astrocytoma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- pilocytic astrocytoma
- age_years
- 3.6
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.656
- INFLAMMATORY_RESPONSE+0.623
- IL6_JAK_STAT3_SIGNALING+0.611
- INTERFERON_GAMMA_RESPONSE+0.582
- TNFA_SIGNALING_VIA_NFKB+0.554
- INTERFERON_ALPHA_RESPONSE+0.528
- KRAS_SIGNALING_UP+0.489
- IL2_STAT5_SIGNALING+0.487
- ANGIOGENESIS+0.485
- COMPLEMENT+0.466
Top 10 suppressed
- E2F_TARGETS-0.491
- G2M_CHECKPOINT-0.473
- OXIDATIVE_PHOSPHORYLATION-0.347
- DNA_REPAIR-0.304
- MYC_TARGETS_V1-0.270
- MITOTIC_SPINDLE-0.239
- SPERMATOGENESIS-0.187
- PEROXISOME-0.090
- MYC_TARGETS_V2-0.085
- FATTY_ACID_METABOLISM-0.061
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
3 twins match this tumor's tissue · 7 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_55JW3HFM | Ganglioglioma | — | 0.943 |
| 2 | BS_769BDPDB | pilocytic astrocytoma | — | 0.942 |
| 3 | BS_MF9X3PKH | low-grade glioma | — | 0.942 |
| 4 | SJEPD009_D.RNA-Seq | EPN | Posterior Fossa EPN | 0.938 |
| 5 | BS_AP0SZ364 | low-grade glioma | — | 0.927 |
| 6 | BS_E4GC9EXR | Ganglioglioma | — | 0.925 |
| 7 | BS_JH29M4KG | pilocytic astrocytoma | — | 0.922 |
| 8 | BS_S7CZY2CH | low-grade glioma | — | 0.921 |
| 9 | BS_V89HGTET | pilocytic astrocytoma | — | 0.919 |
| 10 | BS_E94QRJDW | low-grade glioma | — | 0.919 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 38 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.656 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.623 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.611 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.582 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.554 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.528 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.489 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.487 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.485 | Remibrutinib | — uncovered |
| COMPLEMENT | 0.466 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.462 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.447 | Inavolisib | — uncovered |
| COAGULATION | 0.429 | Binimetinib | — uncovered |
| APOPTOSIS | 0.395 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.386 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.385 | Temsirolimus | — uncovered |
| TGF_BETA_SIGNALING | 0.383 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.367 | Idelalisib | — uncovered |
| HYPOXIA | 0.331 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.324 | Inavolisib | — uncovered |